On December 6, 2024, our CEO Nobuyuki Arakawa gave a presentation on the development of cell and gene therapy using ex vivo expansion technology for hematopoietic stem cells at the pitch event “TCI-VENTURE AWARD 2024 Final”, and won the grand prize in the startup category.
